Apogee Therapeutics, Inc. (APGE) Earnings Call Transcripts

Apogee Therapeutics, Inc.'s Latest Earnings Call - June 10, 2026

In Q2 2026, Apogee Therapeutics reported significant advancements in its pipeline, particularly with zumilokibart for atopic dermatitis (AD). The company highlighted positive Phase II Part B data, showing robust efficacy with fewer dosing days compared to the standard of care. Apogee also announced a strategic collaboration with Blackstone, securing up to $1.3 billion in capital, which will support commercialization efforts and potential profitability by 2029. The company did not provide specific revenue or earnings figures for the quarter, but management emphasized their strong financial position and strategic flexibility.

Reported metrics

Guidance from management

Management expects to launch zumilokibart by the end of the decade and anticipates achieving profitability by 2029, supported by the capital raised through Blackstone.

What management said

Our #1 goal is to get zumi to as many patients as possible. as quickly as possible. We wake up every day as a company thinking about how to do that and bring this to a first-line launch. We now have the capital to do that and to move quickly and to build the organization to bring zumi to launch, again, not only in AD, but as a pipeline and a product. If a strategic party can convince us that they can do it faster, br...

Operationally, we've been very focused on this. And it comes down to, we think, 2 things. One is the larger end of the trial and also having the larger geographic footprint that resulted in seeing the activity, the efficacy on the deeper order endpoints.

What analysts pressed on

Analysts expressed interest in the strategic rationale behind the Blackstone collaboration and its implications for potential M&A. There were also questions about the durability and depth of response in Phase III trials relative to competitors.

Main topics on the call

• Pipeline Advancements — Apogee reported strong Phase II Part B data for zumilokibart, showing 'robust efficacy across lesional and itch endpoints' with fewer dosing days. The company plans to start Phase III trials in the second half of 2026.
• Strategic Collaboration with Blackstone — Apogee secured up to $1.3 billion in capital through a collaboration with Blackstone, which includes $800 million in royalty financing and $500 million in debt. This capital supports commercialization and potential profi...
• Market Positioning and Strategy — Management emphasized the potential of zumilokibart to become a first-line treatment in a growing $50 billion AD market, with significant differentiation in dosing and efficacy compared to competitors.
• Future Indications and Trials — Apogee plans to explore additional indications for zumilokibart, including asthma and eosinophilic esophagitis (EoE), with Phase II trials starting in the second half of 2026.

Read the full Apogee Therapeutics, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 14 Apogee Therapeutics, Inc. earnings call transcripts on record, spanning March 5, 2024 to June 10, 2026. Based on this history, Apogee Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

APGE

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

14

First call

March 5, 2024

Most recent

June 10, 2026

Reporting cadence

quarterly